Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Medullary 2Zollinger-Ellison Syndrome 1Vipoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplastic Syndromes, Hereditary 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Glioblastoma 1Congenital Abnormalities 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Birt-Hogg-Dube Syndrome 1Advanced Malignant Solid Neoplasm 1

Interventions

Magnetic Resonance Spectroscopy 6Iodine-131 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3Trastuzumab 2Sorafenib 2Radiotherapy 2trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1omipalisib 1gallium Ga 68 dotatate 1cediranib 1cabozantinib 1aldesleukin 1aflibercept 1Vorinostat 1Triiodothyronine 1Thyrotropin Alfa 1Tamoxifen 1Sunitinib 1Specimen Handling 1Rosiglitazone 1Ritonavir 1Radiofrequency Ablation 1Pharmacogenomic Testing 1Nivolumab 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Cancer, Papillary × Everolimus × Clear all
NCT01118065 2013-08-12

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
42 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡